India’s largest drugmaker is building a wider presence beyond traditional generics, backed by specialty therapies, pipeline ...

The country's largest drugmaker posted a profit after tax (PAT) of Rs 2,714 crore in Q4 FY26 compared with Rs 2,149.9 crore ...

Sun Pharma’s proposed $11.75 billion acquisition of Organon could reshape its global growth strategy by strengthening its ...

Sun Pharma’s $11.75 billion Organon acquisition was much bigger than a typical pharma deal. Once people looked past the ...

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal ...

This article first appeared on GuruFocus. Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) is set to release its Q4 2026 earnings on May 22, 2026. The consensus estimate for Q4 2026 revenue is $145.

Generics juggernaut Sun Pharma is pulling one lot of a chemotherapy drug in the United States as the issue of particulate ...

Organon & Co. (NYSE:OGN) has entered into a definitive agreement to be acquired by Sun Pharmaceutical Industries. The transaction will lead to Organon being delisted from the New York Stock Exchange ...

Firms including Hindalco Industries, Fortis Healthcare, Torrent Pharmaceuticals, Info Edge (India), and TTK Prestige are also ...

Sun Pharma also said the India business gained 0.3 percentage point in market share in FY26, which it described as the ...

Bernstein said Biocon Ltd and Mankind Ltd are its non-consensus 'Underperform' stock ideas. It called Aurobindo Pharma as ...